US Pharma MarketingJ&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Johnson & Johnson has paid $1 billion upfront to buy itself a degrader antibody conjugate platform via the acquisition of Firefly Bio.
Source: FierceBiotech